About Us > Company Profile

The HOB Story

HOB Biotech Group is a leading manufacturer in China and has emerged as a first-class global company in allergy and autoimmune in vitro diagnostics.

In 2007, entrepreneurs with education and decades of industrial experience in the US started to distribute American and European products in China. HOB has since established a large-scale, ISO 13485 certified manufacturing facility in Suzhou, China, producing high quality products for Asian markets ranging from Line Immuno Assay (BioLINE) to Enzyme-linked immunosorbent assay (BioLISA). HOB has further established world-class R&D centers in Suzhou, China and California, US, with a well experienced product development team which is up to 60 employees by far and led by scientists with education and decades of R&D experience in IVD diagnosis.


By 2018, with years of dedicated research and efforts, HOB has successfully launched its first fully automated quantitative chemiluminescence analyzer with the most comprehensive autoimmunity menu in China market, known as BioCLIA. BioCLIA implements the most cutting-edge technologies that are available in the autoimmunity diagnostics. In the first five months of 2018, HOB sales grow more than 40% yoy and BioCLIA has become one of the most competitive product lines with the fastest sales growing rate of the company.


HOB competes against the well-known companies from US and Germany who dominated the market not by prices, but through its fundamental paradigm shift into emphasizing quality manufacturing and intensive R&D investment. HOB has arisen into the allergy & autoimmune diagnostic market leader in Asia and a global player in the IVD industry.

Based in Asia, Influencing the World

HOB’s mission is to establish and offer customers a top-tier brand in allergy and autoimmune in vitro diagnostics, with state-of-art technologies, the topnotch quality, and the competitive prices. As a leading manufacturer with strong R&D capability, HOB is expanding its global influence by forming strategic alliances with companies worldwide to provide advanced technology and the most competitive products.

The Future is Here

Allergies and autoimmune diseases affect hundreds of millions of people around the world, with more than 500 million affected in Asia alone. Serological tests render an irreplaceable value for the diagnosis of allergy and autoimmune diseases, yet have been monopolized by a few companies with outdated technologies and excessive costs. HOB is committed to offering advanced diagnostic solutions that will deliver greater value to healthcare providers and patients.

Recognizing unmet needs and the stagnant technology, HOB has developed and recently launched a patented, innovative, fully automated, and random-accessible platform, BioCLIA. BioCLIA is revolutionizing in vitro diagnostics for allergy and autoimmune disease by providing accurate results at a much faster speed, eliminating manual operations, and minimizing the financial burden on healthcare providers and patients.